ImageneBio Q1 net loss $10.6M; cash $117.2M, raised $30M in April private placement

ImageneBio, Inc.

2026-Q1 EPS reported -$0.95

Net loss of $10.6M for Q1 2026, vs $9.1M in Q1 2025; R&D $6.0M, G&A $6.1M.
Cash of $117.2M as of March 31; April private placement raised $30M, extending runway into Q1 2028.
Phase 2b ADAPTIVE trial in AD advancing under amended protocol; topline data anticipated Q4 2027.
Plan to initiate Phase 2 in alopecia areata in 2026; initial data expected 2028, based on proof-of-concept.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ImageneBio, Inc. reported financial results for quarter ended March 31, 2026.

Period: quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, ImageneBio, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211935

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.